Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease

Stroke

Volumn 40, Issue 5, 2009, Pages 1721-1728

  Lavallée, Philippa C ^a   Labreuche, Julien ^a   Gongora Rivera, Fernando ^a   Jaramillo, Arturo ^a   Brenner, David ^a   Klein, Isabelle F ^a   Touboul, Pierre Jean ^a   Vicaut, Eric ^b   Amarenco, Pierre ^a  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL FERNAND WIDAL   (France)

Author keywords

Atorvastatin; Cerebral vasoreactivity; Endothelial dysfunction; Lacunar stroke

Indexed keywords

ATORVASTATIN; PLACEBO; C REACTIVE PROTEIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BRAIN BLOOD VESSEL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; VASODILATATION; AGED; BLOOD; BLOOD PRESSURE; BRACHIAL ARTERY; BRAIN CIRCULATION; CAROTID ARTERY; FACTUAL DATABASE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; STROKE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; BLOOD PRESSURE; BRACHIAL ARTERY; C-REACTIVE PROTEIN; CAROTID ARTERIES; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRROLES; RISK FACTORS; STROKE; TREATMENT OUTCOME; VASODILATION;

EID: 65549102803     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.540088     Document Type: Article

References (38)

1. Bogousslavsky J, Van Melle G, Regli F. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988;19: 1083-1092.
2. Pico F, Labreuche J, Touboul PJ, Leys D, Amarenco P. Intracranial arterial dolichoectasia and small-vessel disease in stroke patients. Ann Neurol. 2005;57:472-479.
3. Diehl RR, Berlit P. Dopplerfunktionstest. Functionelle Dopp-lersonographiein der Neurologie. Berlin/Heidelberg: Springer-Verlag; 1996:41-78.
4. Maeda H, Matsumoto M, Handa N, Hougaku H, Ogawa S, Itoh T, Tsukamoto Y, Kamada T. Reactivity of cerebral blood flow to carbon dioxide in various types of ischemic cerebrovascular disease: evaluation by the transcranial Doppler method. Stroke. 1993;24:670-675.
5. Molina C, Sabin JA, Montaner J, Rovira A, Abilleira S, Codina A. Impaired cerebrovascular reactivity as a risk marker for first-ever lacunar infarction: A case-control study. Stroke. 1999;30:2296-2301.
6. Terborg C, Gora F, Weiller C, Rother J. Reduced vasomotor reactivity in cerebral microangiopathy: a study with near-infrared spectroscopy and transcranial Doppler sonography. Stroke. 2000;31:924-929.
7. Pretnar-Oblak J, Sabovic M, Sebestjen M, Pogacnik T, Zaletel M. Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions. Stroke. 2006;37:2540-2545.
8. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004;35:2708-2711.
9. Sterzer P, Meintzschel F, Rosler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke. 2001;32:2817-2820.
10. Fisher CM. Lacunar infarcts. A review. Cerebrovasc Dis. 1991;1: 311-320.
11. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. The GENIC Investigators. Stroke. 2000;31:1634-1639.
12. Herve D, Gautier-Bertrand M, Labreuche J, Amarenco P. Predictive values of lacunar transient ischemic attacks. Stroke. 2004;35: 1430-1435.
13. Fulesdi B, Limburg M, Bereczki D, Kaplar M, Molnar C, Kappelmayer J, Neuwirth G, Csiba L. Cerebrovascular reactivity and reserve capacity in type II diabetes mellitus. J Diabetes Complications. 1999;13:191-199.
14. Ficzere A, Valikovics A, Fulesdi B, Juhasz A, Czuriga I, Csiba L. Cerebrovascular reactivity in hypertensive patients: a transcranial Dopp-ler study. J Clin Ultrasound. 1997;25:383-389.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EF; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National High Blood Pressure Education Program Coordination Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
16. Haute Autorite de sante. Recommandations professionnelles. Traitement medicamenteux du diabete de type 2. Available at: www. has-sante.fr. Accessed October 10, 2008.
17. Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM. Noninvasive assessment of CO2-induced cerebral vasomotor response in normal individuals and patients with internal carotid artery occlusions. Stroke. 1988; 19:963-969.
18. Bonnin P, Ben Driss A, Benessiano J, Maillet A, Pavy le Traon A, Levy BI. Enhanced flow-dependent vasodilation after bed rest, a possible mechanism for orthostatic intolerance. Eur J Appl Physiol OccupPhysiol. 2001;85:420-426.
19. Lavallee PC, Bonnin P, Labreuche J, Amarenco P, Levy B. Flow-mediated vasodilatation of carotid and brachial arteries in healthy subjects and in lacunar stroke patients. Ultrasound Med Biol. 2006; 32:1165-1169.
20. Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J. A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci. 1993;114:7-12.
21. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endo-thelium-dependent coronary vasomotion. N Engl J Med. 1995;332: 488-493.
22. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endo-thelium in patients with coronary artery disease. N Engl J Med. 1995; 332:481-487.
23. Dupuis J, Tardif JC, Rouleau JL, Ricci J, Arnold M, Lonn E, Roux R, Title LM, Amyot R, Bonafede N, Woo A, Cannon CP. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol. 2005;96:1207-1213.
24. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233.
25. van Venrooij FV, van de Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2002;25:1211-1216.
26. Beishuizen ED, Tamsma JT, Jukema JW, van de Ree MA, van der Vijver JC, Meinders AE, Huisman MV. The effect of statin therapy on endo-thelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2005;28:1668-1674.
27. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
30. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000;20: 1047-1051.
31. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol. 2000;20:1052-1056.
32. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32:2575-2579.
33. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N EnglJ Med. 2006;355:549-559.
34. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21:1712-1719.
35. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49:792-798.
36. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003;23:729-736.
37. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999;100:2131-2134.
38. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis. 2001;155: 245-250.